KRAS as a Therapeutic Target

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841

Dragging ras back in the ring

Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744

Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer

Yang, K., Li, C., Liu, Y., Gu, X., Jiang, L., & Shi, L. (2022) · Cells · doi:10.3390/cells11091427 · Cited by 10

Rapid discrimination of colon cancer cells with single base mutation in KRAS gene segment using laser tweezers Raman spectroscopy

Liu, M., Liu, X., Huang, Z., Tang, X., Lin, X., Xu, Y., Chen, G., Kwok, H. F., Lin, Y., & Feng, S. (2018) · Journal of Biophotonics · doi:10.1002/jbio.201800332 · Cited by 10

RNF141 interacts with KRAS to promote colorectal cancer progression

Zhang, J., Jiang, X., Yin, J., Dou, S., Xie, X., Liu, T., Wang, Y., Wang, S., Zhou, X., Zhang, D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01877-4 · Cited by 10

Pharmacological Effects of Grifolin: Focusing on Anticancer Mechanisms

Bouyahya, A., Allam, A. E., Zeouk, I., Taha, D., Zengin, G., Goh, B. H., Catauro, M., Montesano, D., & Omari, N. E. (2022) · Molecules · doi:10.3390/molecules27010284 · Cited by 10

Direkte Modulation von Aktivität und Funktion kleiner GTPasen

Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie · doi:10.1002/ange.201504357 · Cited by 9

Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents

Gangapuram, M., Eyunni, S., Zhang, W., & Redda, K. K. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210112122913 · Cited by 9

Emerging Treatment Strategies in Pancreatic Cancer

Trunk, A. D., Miotke, L. K., Nevala-Plagemann, C., Verdaguer, H., Macarulla, T. M., & Garrido‐Laguna, I. (2021) · Pancreas · doi:10.1097/mpa.0000000000001845 · Cited by 11

Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer

Sciver, R. E. V., Njogu, M. M., Isbell, A. J., Odanga, J. J., Bian, M., Svyatova, E., van Reesema, L. L. S., Zheleva, V. P., Eisner, J., Bruflat, J. K., et al. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00012-6 · Cited by 9

The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges

Shao, Y., Ma, L., Zhang, T., Xu, T., Ye, Y., & Liu, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828162217 · Cited by 12

K-ras peptide mimotope induces a humoral immune response against G12V K-ras antigen in BALB/c mice

Hoo, W. P. Y., Siak, P. Y., Alias, N. A. R., Wong, J. J., Tan, E. W., Song, A. A., Rahim, R. A., & In, L. L. A. (2020) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2020.028.3.03 · Cited by 9

High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma

Russ, E. U., Bhuvaneshwar, K., Wang, G., Jin, B., Gage, M. M., Madhavan, S., Gusev, Y., & Upadhyay, G. (2021) · Oncotarget · doi:10.18632/oncotarget.27880 · Cited by 9

Colorectal cancer-derived exosomes and modulation KRAS signaling

Wan, Y. H., Liu, Q. S., Wan, S. S., & Wang, R. W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02877-w · Cited by 9

Differential functions of the KRAS splice variants

Rossi, J. A. K., Nuevo‐Tapioles, C., & Philips, M. R. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221347 · Cited by 8

Targeted degradation of KRAS protein in non‐small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles

Wang, X., Su, L., Niu, C., Li, X., Wang, R., Li, B., Liu, S., & Xu, Y. (2024) · Drug Development Research · doi:10.1002/ddr.22241 · Cited by 8

Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis

Messina, S. (2018) · Small GTPases · doi:10.1080/21541248.2018.1502591 · Cited by 8

Recent advances in lung cancer genomics: Application in targeted therapy

Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 9

Enhanced CNN Model for Pancreatic Ductal Adenocarcinoma Classification Based on Proteomic Data

Laxminarayanamma, K., Krishnaiah, R. V., & Sammulal, P. (2022) · Ingénierie des systèmes d information · doi:10.18280/isi.270115 · Cited by 9

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS

Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · eLife · doi:10.7554/elife.79747 · Cited by 7

KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers

Doherty, G. J., Kerr, E. M., & Martins, C. P. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.005 · Cited by 8

Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression

Song, J., Seo, H., Kim, M.-R., Lee, S.-J., Ahn, S., & Song, M. (2020) · Molecules · doi:10.3390/molecules25122864 · Cited by 8

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

Booth, L. A., Roberts, J. L., Kirkwood, J. M., Poklepovic, A. S., & Dent, P. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2017.11.004 · Cited by 8

Direct KRAS inhibition: progress, challenges, and a glimpse into the future

Grapsa, D., & Syrigos, K. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760093 · Cited by 8

Deciphering allosteric mechanisms in KRAS activation: insights from GTP-induced conformational dynamics and interaction network reorganization

Zhao, D.-R., Yang, J.-T., Liu, M.-T., Yang, L.-Q., & Sang, P. (2025) · RSC Advances · doi:10.1039/d4ra07924h · Cited by 8

Effect of Secretion Efficiency of Mutant KRAS Neoantigen by Lactococcus lactis on the Immune Response of a Mucosal Vaccine Delivery Vehicle Targeting Colorectal Cancer

Alias, N. A. R., Hoo, W. P. Y., Siak, P. Y., Othman, S. S., Alitheen, N. B., In, L. L. A., Rahim, R. A., & Song, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108928 · Cited by 7

KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor

Wu, N., Huang, Y., Liu, F., Xu, X., Liu, B., & Wei, J. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-617 · Cited by 7

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Pang, X., & Liu, M. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0154-7 · Cited by 7

A Spatial Mapping Algorithm with Applications in Deep Learning-Based Structure ClassificationPreprint

Corcoran, T., Zamora‐Resendiz, R., Liu, X., & Crivelli, S. N. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1802.02532 · Cited by 18

Evaluation of molecular glue–induced neomorphic protein-protein interaction with a cell lysate–based time-resolved fluorescence resonance energy transfer assay

Mo, X., Du, Y., & Fu, H. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100003 · Cited by 6

Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise

Alanazi, F. E., Alatawi, Y. M., Alattar, A., Alshaman, R., Kotb, A. A., & Hetta, ‏. F. (2025) · Pharmaceuticals · doi:10.3390/ph18121788 · Cited by 8

Identification of seven hypoxia-related genes signature and risk score models for predicting prognosis for ovarian cancer

Huang, Y. Y., Zhou, Y., & Zhang, M. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-022-00956-3 · Cited by 6

SNHG14 facilitates cell proliferation in colorectal cancer through targeting KRAS via Hippo-YAP signaling

Shen, M., Su, Y., Song, S., Liu, D., Liu, Z., Chen, D., Pan, Y., Zhang, L., & Xu, X. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.3.8 · Cited by 6

Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies

Bueno, A., Morilla, I., Díez, D., Moya‐García, A. A., Lozano, J., & Ranea, J. A. G. (2016) · Oncotarget · doi:10.18632/oncotarget.12416 · Cited by 5

Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma

Tsirulnikov, K., Duarte, S. M., Ray, A., Datta, N. N., Zarrinpar, A., Hwang, L. H., Faull, K. F., Pushkin, A., & Kurtz, I. (2017) · Journal of Cancer · doi:10.7150/jca.21747 · Cited by 6

Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy

Gong, H., Nie, D., & Li, Z. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620999200816130218 · Cited by 6

Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer

Li, X., Lu, Y., Ou, X., Zeng, S., Wāng, Y., Qi, X., Zhu, L., & Liu, Z. (2020) · PeerJ · doi:10.7717/peerj.10182 · Cited by 6

Anthraquinones as Inhibitors of SOS RAS-GEF Activity

Fernández‐Medarde, A., Fuentes‐Mateos, R., García‐Navas, R., Juan, A. O.-S., Sánchez-López, J. M., Fernández-Medarde, A., & Santos, E. (2021) · Biomolecules · doi:10.3390/biom11081128 · Cited by 6

Dissociation of the Signaling Protein K‐Ras4B from Lipid Membranes Induced by a Molecular Tweezer

Li, L., Erwin, N., Möbitz, S., Niemeyer, F. C., Schrader, T. H., & Winter, R. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901861 · Cited by 6

Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics

Crintea, A., Bocșan, I. C., Jianu, M. E., Şovrea, A. S., Munteanu, C., Kubelac, P. M., Craciun, A. M., & Silaghi, C. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062311 · Cited by 5

Argonaute 2 modulates EGFR–RAS signaling to promote mutantHRASandNRAS-driven malignancies

Siebenaler, R. F., Chugh, S., Waninger, J. J., Dommeti, V. L., Kenum, C., Mody, M. K., Gautam, A., Patel, N., Chu, A., Bawa, P., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac084 · Cited by 5

Synergy and anti‐cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS‐RGL1

Hacisuleyman, A., & Erman, B. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26657 · Cited by 5

Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in PreclinicalIn VivoModels

Weidle, U. H., & Nopora, A. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20265 · Cited by 5

Molecular Mechanisms of Cystic Neoplasia

Papadopoulos, N., & Hruban, R. H. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch75 · Cited by 5

Etiopathogenesis and Treatment of Colorectal Cancer

Bocchi, M., Fernandes, E. V., Pereira, N. D. S., & Amarante, M. K. (2025) · Immuno · doi:10.3390/immuno5030031 · Cited by 5

Diffusion-based determination of protein homodimerization on reconstituted membrane surfaces

Jepson, T. A., & Chung, J. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.3.228 · Cited by 4

The impact of RAS mutation on the treatment strategy of colorectal cancer

Pirvu, E. E., Severin, E. M., Niţă, I., & Toma, Ş. A. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2408 · Cited by 4

Cellular processes involved in lung cancer cells exposed to direct current electric field

Li, H., Liu, S., Yang, X., Du, Y., Luo, J., Tan, J., & Sun, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-62332-0 · Cited by 4

Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations

Yunos, R. I. M., Mutalib, N. A., Khoo, J.-S., Saidin, S., Ishak, M., Syafruddin, S. E., Tieng, F. Y. F., Yusof, N. F. M., Razak, M. R. A., Nadzir, N. M., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.997747 · Cited by 4

Establishment and validation of a sensitive LC–MS/MS method for the quantification of KRASG12C protein PROTAC molecule LC‐2 in rat plasma and its application to in vivo pharmacokinetic studies of LC‐2 PEGylated liposomes

Wang, Y., Wang, Z., Wang, X., Li, X., Liu, X., Zhang, X., & Liu, S. (2023) · Biomedical Chromatography · doi:10.1002/bmc.5629 · Cited by 4

Evidence for a proximal site of action of atrial natriuretic peptide in man.

Semmekrot, B. A., Theelen, B., & Monnens, L. (1990) · PubMed · Cited by 4

Recent advances in therapeutic strategies of Erdheim-Chester disease

Doke, R. R., Lokhande, R. P., Chande, K., Vinchurkar, K., & Prajapati, B. G. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03769-2 · Cited by 3

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models

de Nóbrega, D. F., Eiler, L. C., Ahirwar, P., Nallapu, S., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., et al. (2025) · Cancers · doi:10.3390/cancers17182958 · Cited by 5

Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines

Dragnev, K. H., Lubet, R. A., Miller, M. S., Sei, S., Fox, J. T., & You, M. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0027 · Cited by 3

KRAS: Structure, function, and development of anticancer drugs

Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models

Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 4

Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis

Dodin, Y. (2023) · Medicine · doi:10.1097/md.0000000000036084 · Cited by 3

Interaction of KRas4B protein with C6-ceramide containing lipid model membranes

Li, L., Dwivedi, M., Erwin, N., Möbitz, S., Nußbaumer, P., & Winter, R. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.01.016 · Cited by 3

Targeting molecular subtypes in solid cancers: successes and failures

Assi, R. E., Kotecki, N., & Awada, A. H. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000670 · Cited by 3

Mutant Allele Imbalance in Cancer

Bielski, C. M., & Taylor, B. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051320-124252 · Cited by 3

High expression of the LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: A comprehensive TCGA analysisPreprint

Tian, C., LI, X., & Ge, C. (2021) · Research Square · doi:10.21203/rs.3.rs-361646/v1 · Cited by 3

RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of RAS Genes and Ras Proteins in Housekeeping and Tumorigenesis

McDonald, R. A., Varela-Ramı́rez, A., & Ashley, A. K. (2025) · Biology · doi:10.3390/biology14080936 · Cited by 2

Development of potent inhibitors against KRAS, its mutant G12R, allosteric and Switch-I/Switch-II site

Yadav, V., Kashif, M., Sharma, S., & Subbarao, N. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00415-4 · Cited by 2

Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project

Osawa, T., Matsubara, N., Kato, T., Shiota, M., Nishimoto, K., Abe, T., Shinohara, N., Yasumizu, Y., Tanaka, N., Oya, M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01154-7 · Cited by 2

KRAS Mutation Reduces Thymoquinone Anticancer Effects on Viability of Cells and Apoptosis

Yenigun, V. B., Acar, H., Kanımdan, E., Yenigün, A., Koçyiğit, A., & Çora, T. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230517123807 · Cited by 2

Combinatorial Anti-Cancer Effect of Polypurine Reverse Hoogsteen Hairpins against KRAS and MYC Targeting in Prostate and Pancreatic Cancer Cell Lines

Valiuska, S., Elder, K. K., McKay, S. J., Ciudad, C. J., Noé, V., & Brooks, T. A. (2024) · Genes · doi:10.3390/genes15101332 · Cited by 2

Precision Medicine Based on Next-Generation Sequencing and Master Controllers

Dukleska, K., Yeo, C. J., Pishvaian, M. J., & Brody, J. R. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_71 · Cited by 2

Molecular Mechanisms of Cystic Neoplasia‐

Papadopoulos, N., & Hruban, R. H. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch82 · Cited by 2

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaPreprint

Bandi, D. S. R., Nagaraju, G. P., Sarvesh, S., Carstens, J. L., Foote, J. B., Graff, E. C., Fang, Y.-H. D., Keeton, A. B., Chen, X., Berry, K. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.04.616725 · Cited by 2

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsPreprint

de Nóbrega, D. F., Eiler, L. C., Ahirwar, P., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., Piazza, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.25.640132 · Cited by 2

Interaction between microRNA and KRAS in Glioblastoma

Beylerli, O., Мусаев, Э. Р., Soto, G. R., Castillo-Rangel, C., Ramírez, M. D. J. E., & Ilyasova, T. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673343892241207034138 · Cited by 1

Computational investigation of stigmasterol as a potential therapeutic agent for cervical cancer: insights from density functional theory (DFT) and molecular docking studies

Udoh, E. S., Stephanie, M. I., Otuonye, F., Oluwadamilola, D., & Lazarus, A. A. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00361-1 · Cited by 1

Cellular Identification of Single‐Base Mutations in KRAS Gene Fragments Based on Nonhomologous Spectroscopic Data Fusion Modeling

Wang, C., Abudureyimu, A., Zhang, Q., You, W., Li, D., Jia, X., Zhang, Y., Chen, C., Hu, R., Wang, M., et al. (2025) · Journal of Biophotonics · doi:10.1002/jbio.202500239 · Cited by 1

Mechanistic insights into KRAS G12D inhibitor binding revealed by molecular dynamics simulations of multiple crystal structures

Kim, D. H., Lee, E. K., & Lee, S. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp03384e · Cited by 3

Examining the Outcomes of Palliative Oophorectomy of Ovarian Metastases in de-Novo Metastatic Colorectal Cancer and Its Association with RAS Mutation Status: Insights from a Single-Institution Perspective

Alawabdeh, T., Al-Ya’goub, M., Hamo, K. M., Al-Masri, Y., Turfa, R., Alnassarwin, S., Masadeh, H., Khader, R., & Mubaydeen, T. (2025) · Cancer Management and Research · doi:10.2147/cmar.s495321 · Cited by 1

Targeted Therapy and Precision Medicine

Tasian, S. K., & Hunger, S. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_8 · Cited by 1

Systems approaches for identifying disease genes and drug targets

Srihari, S. (2017) · Methods · doi:10.1016/j.ymeth.2017.10.002 · Cited by 1

Molecular Pathology of Lung Tumors

Popper, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-55743-0_19 · Cited by 1

Targeted phosphoproteomics of the Ras signaling network reveal regulatory mechanisms mediated by oncogenic KRASPreprint

Urisman, A., Yuan, T. L., Trinidad, M. I., Morris, J. H., Afghani, S., Osés-Prieto, J. A., Ritchie, C. D., Zahari, M. S., Benes, C. H., Burlingame, A. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/695460 · Cited by 1

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RASPreprint

Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.489309 · Cited by 1

Molecular Understanding of the Development of Ductal Pancreatic Cancer

Lee, J. W., Hruban, R. H., & Wood, L. D. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch119 · Cited by 1

Molecular Understanding of Development of Ductal Pancreatic Cancer

Wood, L. D., & Hruban, R. H. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch90

Biological Events and Barriers to Effective Delivery of Cancer Therapeutics

Bozeman, E. N., & Yang, L. P. H. (2018) · Bioanalysis · doi:10.1007/978-3-030-01775-0_2

DDPCR SCREENING FOR THE MUTATIONAL STATUS OF THE BRAF AND KRAS GENES IN PATIENTS OF SOUTHERN RUSSIA

Vodolazhskiy, D. I., Владимирович, Г. Г., Федорович, Ф. Е., Алексеевич, М. Р., & Викторович, К. Д. (2019) · Современные проблемы науки и образования · doi:10.17513/spno.28576

Explorando a quinase IKK como um alvo terapêutico para células iniciadoras de tumor pulmonares induzidas pelo oncogene KRAS

Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111

Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regressionPreprint

Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/807578

What Are the New Challenges of the Current Cancer Biomarkers?

Chen, J., Yang, L., Duan, Y., Pu, T., Zheng, S., Liu, F., Huang, K., Mirt, G., & Xu, F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89976

Biology of Pancreas and Possible Diseases

Srivani, G., Dariya, B., Farran, B., Alam, A., & Nagaraju, G. P. (2019) · Springer eBooks · doi:10.1007/978-981-32-9393-9_1

The phylogenetic functional conservation of Drosophila Seven-In-Absentia (SINA) E3 ligase and its two human paralogs, SIAH1 and SIAH2, in Drosophila eye developmentPreprint

Sciver, R. E. V., Cao, Y., & Tang, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.28.067074

With AMG 510, the Treatment of Non Small Cell Lung Cancer Has Been ChangedPreprint

Mukherjee, D. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3572550

Peer Review #1 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.2)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.2/reviews/1

Peer Review #1 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.1/reviews/1

Leveraging a Joint of Phenotypic and Genetic Features on Cancer Patient SubgroupingPreprint

Oniani, D., Wang, C., Zhao, Y., Wen, A., Liu, H., & Shen, F. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2103.16316

In-Silico Analysis of The Correlation Between PD-L1 and Pro-Inflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma

Ünver, N. (2021) · Acta Medica · doi:10.32552/2021.actamedica.559

Peer Review #3 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.2)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.2/reviews/3

Peer Review #2 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.1/reviews/2

Peer Review #3 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.3)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.3/reviews/3

Peer Review #3 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.1/reviews/3

Peer Review #2 of "Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer (v0.2)"

(2020) · PeerJ · doi:10.7287/peerj.10182v0.2/reviews/2

Precision Medicine Based on Next Generation Sequencing and Master Controllers

Dukleska, K., Yeo, C. J., Pishvaian, M. J., & Brody, J. R. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_71-1

PKC-alpha promotes phosphorylation of KRAS suppressing its oncogenic propertiesPreprint

Joglekar, T., Ku, A., Schollaert, E., Gong, Y., Stewart-Ornstein, J., Urisman, A., & Wang, M.-T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.24.493257

Antibody-mediated delivery of anti-KRAS-siRNA overcomes therapy resistance in colon cancer

Wang, C., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00003-1

Targeting cytokine networks in KRAS-driven tumorigenesis

Golay, H. G., & Barbie, D. A. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.928596 · Cited by 20

Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18

KRAS: A Promising Therapeutic Target for Cancer Treatment

Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 41

Targeting the MAPK pathway in KRAS-driven tumors

Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512

Targeting the untargetable KRAS in cancer therapy

Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366